Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

The China-Japan Friendship Hospital (Chinese: 中日友好医院) was established through the cooperation of the Chinese and Japanese governments during the 1980s. The hospital has been directly affiliated with China's Ministry of Health since its first day of operation, October 23, 1984. The hospital is located on East Yinghuayuan Street, Chaoyang District, Beijing. The hospital covers 9.7 hectares, with floorspace of facilities measuring 180,000 square meters. Within the hospital, there are 1,500 beds, 58 departments, as well as a clinical research and education center. The hospital has intensive care and treatment of severe diseases as a primary focus and integrative eastern-western medicinal therapy as an additional area of expertise. The hospital often attends to the health care of senior officials from over 100 countries and regions.

Beijing Xianyun Qiyuan Technology Co., Ltd., established on 2018-07-13, Business scope includes technology promotion,technology transfer,technology development,technical consulting,Technical Services;software development;Computer System Services;selling computers,Software and Auxiliary Equipment,electronic product,Equipment,Office Supplies,communication equipment(Without satellite ground reception,launch device),Instrumentation;Business Management Consulting;Enterprise Marketing Planning;Sales of Class III Medical Devices.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Sales of Class III medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Guangzhou Fuda Cancer Hospital is a tertiary specialized cancer hospital which is affiliated with the Health Department of Guangdong Province in China. It was designated a national key clinical (cancer) hospital by the National Health and Family Planning Commission in 2011. The same year, Guangzhou Fuda Cancer Hospital was honored with National Trustworthy Private Hospital by the National Institute of Hospital Administration. In 2012, China Hospital Association rated Guangzhou Fuda Cancer Hospital as China Public Confidence Model Hospital. It was accredited by JCI in 2014.

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Beijing Shenggu Tongchuang Technology Development Co., Ltd., established on 2012-02-28, Business scope includes technology development,technology transfer,technical consulting,Technical Services;Medical Research and Experimental Development;Sales of chemical products(Does not contain dangerous chemicals and a class of precursor chemicals);Import and export,Agent import and export,Technology Import and Export;Sales of medical devicesI,II,IIIkind.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Chongqing Proton Genetic Medicine Research Institute Co., Ltd., established on 2017-05-27, Business scope includes licensed projects:Clinical Cytomolecular Genetic Testing,pathology testing,Clinical Laboratory Services;Medical Network Information Service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Medical Research and Experimental Development(Does not contain items requiring permits or approvals);Gene detection technology and biological reagent research,Development and technology transfer(Does not contain items requiring permits or approvals);Bioengineering technology development,consult,comminicate,transfer,Promotion service(Does not contain items requiring permits or approvals);Health Information Consultation.[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments](Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

ChromaXome Corp, part of TerraGen Diversity, Inc., is an American company. The firm provides drug discovery in the emerging field of combinatorial biosynthesis. TerraGen Diversity, Inc. acquired ChromaXome Corp from Trega Biosciences, Inc. on March 15, 1999 for $6.03 million.

Xiamen Spacegen Co. Ltd. is a Chinese company. The firm develops, manufactures and sells cancer, genetic disease and precision medical testing products.

Suzhou Genga Biomedical Engineering Co., Ltd., established on 2016-08-26, Business scope includes biomedicine,R&D of medical devices,Production,Sales;biotechnology development,technical consulting,technology transfer,Technical Services;laboratory consumables,laboratory reagent,Instrumentation(Does not include measuring instruments),computer,Sales of software, hardware and auxiliary equipment;Engage in the import and export of the above commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Machinery and Equipment Leasing;Medical equipment rental;Non-residential real estate leases(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Longping Youliang (Tianjin) Co., Ltd., established on 2005-12-28, Business scope includes research and industrialization of new crop varieties;crop seed production;Industrialization of Deep Processing Technology of Agricultural Products and Sales of Products;Research on animal husbandry technology and production of animal products,Sales;biological fertilizer,pesticide(except dangerous goods),feed sales;Production of grain and oil processing equipment,Sales;Grain Purchase,Sales;Wholesale Rice Seeds,retail;Crop Seed Wholesale,retail;Import and export,Technology Import and Export(Except for national special control projects);Wholesale and retail of rice;Agricultural Technology Consulting Services,Information consulting services and related training;Biotechnology Services;Business Incubation Services;Own house rental;property management;Financial Advisory Services;Wholesale and retail of compound fertilizer;crop planting(Operation of branches outside the restricted area);Own Vehicle Rental(Except finance lease);Warehousing Services(Free of Hazardous Chemicals,Flammable and explosive precursors).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shenzhen Jiyinga Medical Laboratory, established on 2018-07-13, Business scope includes general business items:medical service;technology development,Technical Services,technology transfer,technical consulting;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Medical Research and Experimental Development;health management;Health Advisory;Sales instrumentation,Equipment,Chemical Products(Free of Hazardous Chemicals),Computer hardware and software and auxiliary equipment;Import and export,Technology Import and Export,Agent import and export;Investment.(Enterprises independently choose operating projects according to law,Carry out business activities;Medical services and items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.),The licensing program is:First,two,Production of Class III Medical Devices,Sales.

BGI Qinglan Biotechnology (Wuxi) Co., Ltd., established on 2012-05-10, The business scope includes splicing design and technology development of biological gene products,Technical Services,technical consulting;General Machinery,Computer software and auxiliary equipment,Sales of Medical Devices;General machinery and equipment rental;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Sino Mdgene is committed to providing the clinic products and services.  It has created various business segments, such as pharmacogenomics, pathogenic microbes, and tumour liquid biopsy. They offer early tumour screening, targeted drug detection for cancers, tumour drug resistance monitoring, and other services.

Affymetrix, Inc. was an American company that manufactured DNA microarrays; it was based in Santa Clara, California, United States. The company was acquired by Thermo Fisher Scientific in March 2016. The company was founded by Stephen Fodor in 1992. It began as a unit in Affymax N.V. in 1991 by Fodor's group, which had in the late 1980s developed methods for fabricating DNA microarrays, called "GeneChip" according to the Affymetrix trademark, using semiconductor manufacturing techniques. The company's first product, an HIV genotyping GeneChip, was introduced in 1994 and the company went public in 1996. As a result of its pioneering work and the ensuing popularity of microarray products, Affymetrix derived significant benefit from its patent portfolio in this area.

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec. The company was established in 2001 and is based in Cambridge, Massachusetts.

Yield10 Bioscience, Inc. is an agricultural bioscience company, which engages in the development of oilseed Camelina sativa as a platform crop for large scale production of low carbon sustainable seed products. The company was founded by Anthony J. Sinskey, Simon F. Williams, and Oliver P. Peoples in 1992 and is headquartered in Woburn, MA.

Servier are driven by the belief in the excellence of their profession. Theirs is a research-based organization, fulfilling a basic need and dedicated to the future.